Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient, infection, and treatment characteristics

From: Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

 Colistin + levofloxacin group (n = 120)Meropenem + levofloxacin group (n = 112)p value
Age, years (n = 232)63 [49–71]60.5 [50–70]0.370
Female (n = 232)28 (23.3)31 (27.7)0.448
Underlying diseases (n = 232)41 (34.2)38 (33.9)0.969
 Diabetes mellitus19 (15.8)22 (19.6)0.447
 Chronic liver disease6 (5.0)5 (4.5)0.848
 Congestive heart failure2 (1.7)2 (1.8)0.945
 Chronic renal disease1 (0.8)4 (3.6)0.151
 Chronic obstructive pulmonary disease21 (17.5)10 (8.9)0.055
 Neoplasia5 (4.2)3 (2.7)0.535
Infection characteristics (n = 232)
 Days from MV to VAP8 [6–11]7.5 [6–11]0.844
 Clinical presentation
  Sepsis67 (55.8)62 (55.4)0.992
  Severe sepsis27 (22.5)26 (23.2) 
  Septic shock26 (21.7)24 (21.4) 
 APACHE II trial inclusion—VAP diagnosis19 [14–24]17 [13–22]0.065
  APACHE II ≤ 1540 (33.3)46 (41.1)0.223
  APACHE II > 1580 (66.7)66 (58.9) 
 Multilobar infiltrates (Rx film)69 (57.5)54 (48.2)0.157
 Baseline CPIS6 [4–7]5 [4–7]0.662
 Baseline creatinine clearance (mg/h) (n = 231)101.0 [70.9–131.0]113.0 [66.8–163.4]0.424
 Microbiological diagnosis (n = 157)82 (52.2)75 (47.8)0.824
 VAP caused by A. baumannii, P. aeruginosa, and K. pneumoniae (n = 79)40 (48.8)39 (52)0.811
 MIC distribution
  Meropenem MIC
   ≤ 2 mg/l—susceptible16 (40)18 (46.2)0.719
   > 2–8 mg/l—intermediate4 (10)5 (12.8)
   > 8 mg/l—resistant120 (50)16 (41)
  Colistin MIC
   ≤ 2 mg/l—susceptible235 (87.5)32 (82.1)0.500
   > 2 mg/l—resistant5 (12.5)7 (17.9)
  Levofloxacin MIC
   ≤ 2 mg/l—susceptible16 (40)17 (43.6)0.746
   > 2 mg/l—resistant24 (60)22 (56.4)
 Bacteremia (n = 232)21 (17.5)17 (15.2)0.633
Treatment (n = 232)
 Empirical treatment with vancomycin19 (15.8)19 (17)0.816
 Empirical treatment with linezolid17 (14.8)18 (16.4)0.744
 Appropriate empirical antibiotic treatment (n = 157)65 (79.3)54 (72)0.288
 Duration of antibiotic treatment
  Days of treatment (n = 232)9 [5–14]7.9 [5–11]0.035
  Days of levofloxacin (n = 232)8 [5–13]7 [4–9]0.003
  1. The data are expressed as n, n (%), and the median (IQR) unless otherwise indicated
  2. MV mechanical ventilation, VAP ventilator-associated pneumonia, APACHE Acute Physiology and Chronic Health Evaluation, Rx radiographic film, GNB gram-negative bacilli, CPIS Clinical Pulmonary Infection Score
  3. 1Definition according to the EUCAST 2012 recommendations and criteria. Carbapenem-resistant gram-negative bacteria (MIC > 8 mg/l). Colistin-resistant gram-negative bacteria (MIC > 2 mg/l for A. baumannii and Enterobacteriaceae and > 4 mg/l for P. aeruginosa). EUCAST. Breakpoint tables for interpretation of MICs and zone diameters version 2.0, valid from 2012 to 01-01. http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/
  4. 2Includes P. aeruginosa; all of these isolates had an MIC breakpoint ≤ 4 mg/l (susceptible)